Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 22;63(11):e01692-19.
doi: 10.1128/AAC.01692-19. Print 2019 Nov.

In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations

Natalie S Nunnally  1 , Kizee A Etienne  2 , David Angulo  3 , Shawn R Lockhart  2 , Elizabeth L Berkow  2
Affiliations

In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations

Natalie S Nunnally et al. Antimicrob Agents Chemother. .

Abstract

Ibrexafungerp is a first-in-class glucan synthase inhibitor. In vitro activity was determined for 89 Candida glabrata isolates with molecularly identified FKS1 or FKS2 mutations conferring resistance to the echinocandins. All isolates were resistant to at least one echinocandin (i.e., anidulafungin, caspofungin, or micafungin) by broth microdilution. Results for ibrexafungerp were compared with those for each echinocandin. Ibrexafungerp had good activity against all echinocandin-resistant C. glabrata isolates.

Keywords: Candida glabrata; FKS; SCY-078; antifungal; echinocandins; ibrexafungerp; resistance.

PubMed Disclaimer

References

    1. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, Baughman W, Stein B, Hollick R, Park BJ, Chiller T. 2012. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol 50:3435–3442. doi:10.1128/JCM.01283-12. - DOI - PMC - PubMed
    1. Matsumoto E, Boyken L, Tendolkar S, McDanel J, Castanheira M, Pfaller M, Diekema D. 2014. Candidemia surveillance in Iowa: emergence of echinocandin resistance. Diagn Microbiol Infect Dis 79:205–208. doi:10.1016/j.diagmicrobio.2014.02.016. - DOI - PubMed
    1. Pham CD, Iqbal N, Bolden CB, Kuykendall RJ, Harrison LH, Farley MM, Schaffner W, Beldavs ZG, Chiller TM, Park BJ, Cleveland AA, Lockhart SR. 2014. Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 58:4690–4696. doi:10.1128/AAC.03255-14. - DOI - PMC - PubMed
    1. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724–1732. doi:10.1093/cid/cit136. - DOI - PMC - PubMed
    1. Berkow EL, Angulo D, Lockhart SR. 2017. In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris. Antimicrob Agents Chemother 61:e00435-17. doi:10.1128/AAC.00435-17. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources